Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Navamedic

Less than 1K followers

NAVA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus

Navamedic is a Nordic pharmaceutical company that supplies pharmaceuticals, OTC, medical nutrition products for rare diagnoses and medical devices to hospitals and pharmacies in areas such as obesity, women's health, urology, gastrointestinal and pain. Navamedic operates in the Nordic countries, the Baltics and Benelux but is also represented in the UK and Greece. The company was established in 1999 and is headquartered in Oslo.

Read more
Market cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
23.4.
2026

Interim report Q1'26

23.4.
2026

General meeting '26

14.8.
2026

Interim report Q2'26

All
Press releases
3rd party
ShowingAll content types
Regulatory press release2/27/2026, 12:05 PM

Navamedic ASA: Mandatory notification of trade

Navamedic
Regulatory press release2/27/2026, 12:04 PM

Navamedic ASA: Mandatory notification of trade

Navamedic
Regulatory press release2/12/2026, 6:00 AM

Navamedic ASA: Strong growth and important product launch in Q4 2025

Navamedic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release2/12/2026, 6:00 AM

Navamedic ASA: Strong growth and important product launch in Q4 2025

Navamedic
Regulatory press release2/9/2026, 8:19 AM

Navamedic ASA: Invitation to presentation of fourth quarter 2025 results

Navamedic
Regulatory press release1/19/2026, 1:01 PM

NAVA: Financial calendar

Navamedic
Regulatory press release1/7/2026, 11:35 AM

Navamedic ASA: Minutes of Extraordinary General Meeting

Navamedic
Regulatory press release12/29/2025, 7:23 AM

Grete Roede og Navamedic lanserer nytt vektreduksjonskonsept: Lettere steg

Navamedic
Regulatory press release12/18/2025, 7:48 AM

NAVA: Financial calendar

Navamedic
Regulatory press release12/12/2025, 7:00 AM

Navamedic ASA: Notice of extraordinary general meeting on 7 January 2026

Navamedic
Regulatory press release12/12/2025, 7:00 AM

Navamedic ASA: Notice of extraordinary general meeting on 7 January 2026

Navamedic
Regulatory press release12/9/2025, 12:00 PM

Oslo, December 9, 2025 - Navamedic ASA Introduces Flexilev[®] in OraFID[®]: Enhancing Parkinson's Care with Simplified and Precise Dosing for Personalized Treatment

Navamedic
Regulatory press release12/8/2025, 6:33 AM

Navamedic ASA: Appointment of CFO

Navamedic
Regulatory press release12/8/2025, 6:33 AM

Navamedic ASA: Appointment of CFO

Navamedic
Regulatory press release11/28/2025, 4:05 PM

Navamedic ASA: Resignation of CFO

Navamedic
Regulatory press release11/28/2025, 4:04 PM

Navamedic ASA: Resignation of CFO

Navamedic
Regulatory press release10/28/2025, 6:00 AM

Navamedic ASA: Double digit growth in the 3rd quarter, 2025

Navamedic
Regulatory press release10/28/2025, 6:00 AM

Navamedic ASA: Double digit growth in the 3rd quarter, 2025

Navamedic
Regulatory press release10/24/2025, 3:56 PM

Navamedic ASA: Invitation to 2025 3rd quarter presentation

Navamedic
Regulatory press release10/24/2025, 3:56 PM

Navamedic ASA: Invitation to 2025 3rd quarter presentation

Navamedic
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.